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Abstract
Introduction Childhood obesity is an emerging health
problem. Surgical treatment of obese adolescents, particu-
larly those affected by congenital syndrome, represents a
controversial issue. The aim of this multicenter study was
to retrospectively assess the results of laparoscopic sleeve
gastrectomy (LSG) in a cohort of adolescents affected by
morbid obesity, with or without congenital syndromes.
Materials and methods Forty-one obese (BMI 49 ± 6 kg/
m2) adolescents with mean age of 16 ± 3 years (58.5%
with previous intragastric balloon failure), and subjected to
LSG, were retrospectively evaluated for complications
rate, % excess weight loss (%EWL), and inhibition of co-
morbidities after 2 years of follow-up.
Results All the operations were completed laparoscopi-
cally and no intra-operative complications were recorded.
No mortality was recorded while peri- or post-operative
complications only occurred in two patients (4.9%). The
EWL% at 6, 12, and 24 months were 42.3, 58.3, and 59.4,
respectively. %EWL was comparable (p = 0.7) between
non-syndromic and syndromic obese adolescents at
24 months. Conversely patients with previous intragastric
balloon surgery had a significant lower EWL (%) at
24 month (p\ 0.01). Moreover, at the same time point, co-
morbidity resolution rate was 78.2% while improvement
rate was 57.6%. Specifically, remission rate of type 2
diabetes (T2DM), hypertension and obstructive sleep apnea
(OSA) were 71, 75 and 61%, respectively.
Conclusion LSG is advantageous in the treatment of
morbidly obese juveniles concerning safety, weight loss
and co-morbidity control and at same time presenting, a
possible effective therapeutic option for patients affected
by congenital syndrome.
Keywords Bariatric surgery in teenagers  Childhood
obesity  Sleeve gastrectomy  Adolescents  Syndromic
obesity  Surgical treatment
Introduction
Obesity is the fifth leading risk for global deaths. Child-
hood obesity is a growing public health problem with
grievous long-term consequences. In last 30 years, the
incidence of childhood obesity has been more than doubled
in children and quadrupled in juveniles obese adolescents
are more likely to suffer from several of co-morbidities,
such as type 2 diabetes (T2DM), hypertension, nonalco-
holic steatohepatitis (NASH), sleep apnea (OSA), and
cholelithiasis. In addition, morbid obese adolescents will
very likely become morbid obese adults [1–3]. Moreover,
several studies have documented poor health-related qual-
ity of life (HRQL) in obese children, and the degree of
obesity is related to the perceived impairments in emo-
tional, social, physical, and school functioning. Based on
the last US report, approximately 17% of children and
teenagers (ages 2 to 19) were obese, 31.8% were either
overweight or obese [3] and 6.5% of 12 to 19 year olds
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were morbidly obese [4]. In Italy, an overweight range
between 14.9 and 40.6%, and obesity range between 2.4
and 19.5% have been reported, representing the highest
incidence in Europe [5]. Etiology of childhood obesity is
multifactorial and includes genetic, neuroendocrine,
metabolic, psychological, environmental and socio-cultural
factors. Constitutional obesity and mental retardation co-
occur in several multiple congenital syndromes, including
Prader–Willi (PWS), Bardet–Biedl, Cohen, Albright
hereditary osteodystrophy, and Borjeson–Forssman–Leh-
mann syndrome as well as some rare disorders [6]. Bari-
atric surgery seems to offer, as in adult population,
excellent result in adolescents, gaining progressive con-
sensus in the scientific communities [7–10]. The ASMBS
pediatric committee established in 2012 the selection cri-
teria’s for bariatric procedures in adolescents [11]. Further,
a devoted position statement on bariatric surgery in ado-
lescents was published by the Italian Society of Bariatric
Surgery in 2009, which was subsequently confirmed in
2015 [12]. In the Fourth International Sleeve Gastrectomy
Expert Panel Consensus Statement, 77% of the panelists
identified the laparoscopic sleeve gastrectomy (LSG) as a
valid treatment option in morbidly obese teenagers [13].
The purpose of this study was to evaluate the safety and
effectiveness of LSG in morbid obese adolescents, with or
without congenital syndromes, focusing on complications
rate, weight loss and control of co-morbidities during
2 years of follow-up.
Methods
Definitions, inclusion and exclusion criteria
A multidisciplinary team consisting of a pediatric
endocrinologist, two pediatric bariatric surgeons, three
bariatric surgeons, two dieticians and a psychologist fol-
lowed and assessed the patient’s eligibility for bariatric
surgery. The following inclusion criteria were applied: a
body mass index (BMI) C35 kg/m2 with major co-mor-
bidities or [40 kg/m2 with major/minor co-morbidities,
failure to achieve a weight reduction after proved dieto-
logical treatment only, the presence of a dedicated care-
giver from the patient’s family, a supportive psychological
evaluation in the form of behavioral, cognitive, emotional,
and psychosocial assessments, motivation and realistic
expectations by the patient and their family, the absence of
contraindications for surgery, and informed consent or
parental consent based on patient age [11]. The selected
patients were included in an established program of pre-
operative evaluation with bi-weekly appointment, followed
by psychologists and registered dieticians for a period of
9 months, with constant and mandatory family support to
guarantee the best medical management (reduced-energy
diets with restricted access to food, regular physical
activity), particularly in case of adolescents affected by
syndromic obesity. The failure of this pre-surgical program
was considered contraindications for surgery, as happened
in six cases during our experience in the study period.
Patients were screened for obesity related co-morbidities
following national and international guidelines. Hyperten-
sion was defined as systolic or diastolic blood pressure that
is higher than the 95th percentile for sex, age, and height on
three or more pre-operative visits during the weight man-
agement period. Prehypertension was defined as systolic or
diastolic blood pressure levels between the 90th and 95th
percentiles for age, gender, and height according to the
fourth Report on the Diagnosis, Evaluation, and Treatment
of High Blood Pressure in Children and Adolescents [14].
Dyslipidemia was defined according to the report of the
Expert Panel on Integrated Guidelines for Cardiovascular
Health and Risk Reduction in Children and Adolescents
[15]. Diabetes and prediabetes were diagnosed according to
the American Diabetes Association definition, which
employed a cutoff point of 7.0 mmol/L for diabetes and
5.5 mmol/L for prediabetes [16]. Obstructive sleep apnea
(OSA) and sleep-related breathing disorders were assessed
clinically through the Pediatric Sleep Questionnaire (PSQ)
and were investigated using polysomnography. OSA was
diagnosed in patients who had an apnea/hypopnea index
that was above 2 [17] and a PSQ score above 33 [18]. The
diagnosis of polycystic ovarian syndrome (PCOS) was
established according to the criteria derived from the 1990
National Institute of Child Health and Human Develop-
ment (NICHD) conference and revised in 2003 [19, 20].
Resolution of all co-morbidities was evaluated clinically
and biochemically at each follow-up visit. Remission of
diabetes mellitus was defined as attaining a sustained FPG
level below 7.0 mmol/L, and HbA1c level below 6.5%
while not on anti-diabetes medication [16]. On the other
hand, improvement of diabetes was defined as a decrease in
FPG and/or HbA1c with outreaching normal levels, and/or
a decrease in the dose or frequency of anti-diabetes med-
ications [16]. For dyslipidemia, a level less than 2.8 mmol/
L for LDL and more than 1.2 mmol/L for HDL were
considered as remission, and remission of hypertriglyc-
eridemia was defined as reaching a value within normal
range for age (below 0.8 mmol/L for children below
10 years of age, or below 1.0 mmol/L for those 10 years of
age and older) [15]. With regards to OSA, improvement
and remission were evaluated based on change in the
symptoms collected by the PSQ and finally with
polysomnography, when needed [17, 18]. With regards to
PCOS, improvement and remission were evaluated clini-
cally based on normalization of menstrual disorders and the
absence of signs of hyperandrogenism together with the
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variation of medications dosage. In case of hepatic steatosis
and/or nonalcoholic steatohepatitis (pre-operatively diag-
nosed), the diagnosis was confirmed intra-operatively with
surgical biopsy, managed post-operatively with ultrasound
at six months (finally every six months) and, in selected
cases (severe NASH), re-evaluated with needle-biopsy
ultrasound-guided. Chronic disease (cardiac, renal, pul-
monary) was evaluated by the specialist team, considering
the medications dose reduction as criteria of co-morbidities
improvement.
Patients
Forty-one records of adolescent patients (20 male and 21
female) with mean age of 16 ± 3 years, a minimum fol-
low-up of 24 months, and meeting the inclusion and
exclusion criteria, were extracted from the prospectively
maintained databases of the institutions involved in this
study. All the patients affected by morbid obesity with
mean pre-operative BMI 49 ± 6 kg/m2 (range 39.2–69 kg/
m2) and mean excess weight of 75 ± 18 kg, were sub-
jected to LSG. Seven of these (17.1%) were affected by
syndromic obesity, six PWS and one Bardet–Biedl and
complicated by severe co-morbidities requiring several
hospitalizations. The others were all affected by co-mor-
bidities (77% major). The PWS received neurologic treat-
ment at least for 1 year (two patients with anticonvulsant
therapy and selective serotonin reuptake inhibitor (SSRI);
to piramate and fluoxetine) and were compliant with the
scheduled neurologic and psychiatric treatment.
In 24 of these (58.5%), the first approach was an inte-
grated management of dietician/psychologist support plus
BioEnterics Intragastric Balloon (BIB) placement, but this
was successful only in a 3% (criteria for success
was = excess weight loss (EWL)[10% at 6 months). The
majority of the surgical operation was performed in the
pediatric hospital (33 patients, 80.5%) with daily round of
multidisciplinary group, including bariatric surgeons, to
guarantee specific and expert support during the hospital
stay. The remaining 8 patients (19.5%, age 19) were treated
in the bariatric center with final pre-discharge pediatric
consultation.
Surgical interventions and post-operative
management
LSG was carried out on calibrated 40 Fr bougie, starting
6 cm from pylorus using all reinforced cartridges (syn-
thetic glycolide-trimethylene carbonate copolymer Gore-
Seamguard Bioabsorbable Staple Line Reinforcement)
and obtaining a final sleeve capacity of 90–100 ml (mea-
sured intra-operatively during blue methylene test). The
abdominal drain was placed in 37 out of 41 patients
(90.2%). No nasogastric tube was placed. Three cases
required a posterior cruroplasty with non-absorbable stit-
ches (hiatal hernia repair = HHR) for intra-operative
finding of hiatal defects (7.3%). Methylene blue test, on the
first and second post-operative day (37/41 patients, 90.2%),
or X-ray with soluble oral contrast (Gastrografin) (4/41
patients, 9.8%) were performed as leak test before clear
liquid was started. The follow-up visits were scheduled at
1, 3, 6, 9, 12 months and then in every 6 months. In case of
syndromic obesity, LSG was performed with the intention
to be the first step of biliopancreatic diversion duodenal-
switch (BPD-DS) and the decision to proceed to the second
stage was evaluated case by case after a minimum follow-
up of 12 months. Moreover, this group of the patients was
also examined by the pediatric psychologist who was
present in the office at each post-operative visit.
Data analysis
Statistical analysis was performed with the Statistical
Package for the Social Sciences, version 21.0 (SPSS, Inc.,
Chicago, IL). Descriptive statistics for continuous variables
are presented as mean ± standard deviation. Categorical
data are presented as counts and percentages. The follow-
ing parameters were evaluated as percentages: conversion
rate, intra-operative complications, operative time, hospital
stay, peri- and post-operative complications (classified
according to the Clavien–Dindo scores) [21], EWL, co-
morbidities results (remission, improvement or unmodi-
fied). At two-year time point, descriptive and comparative
analysis was performed between the entire study popula-
tion, the patients affected by syndromic obesity and the
patients with previous history of BIB. Statistical signifi-
cance was set at p\ 0.05.
Results
Anthropometric and clinical characteristics of the study
population are reported in Table 1. All the operations were
completed laparoscopically, and no intra-operative com-
plications were recorded. The mean operative time was
94 ± 35 min. The average post-operative hospital stay was
5.3 ± 2 days. Statistically, significant difference was
recorded between the hospital stay of patients with syn-
dromic obesity, 9 ± 3 days vs. 4.2 ± 1.6 days for non-
syndromic patients (p\ 0.05). No incidence of mortality
was recorded. Peri- or post-operative complications did
occur in two patients (4.9%). First patient was subjected to
LSG ? HHR procedure and developed a transient dys-
phagia (score II) in the first week post-operative. Dyspha-
gia was resolved after 50 days of conservative
management (dietician counseling), prokinetic drug and a
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full dose of proton-pump inhibitors (PPIs) The second
patient, with pre-operative BMI of 68 kg/m2, developed a
trocar site hernia (2.3 cm2 at 12 mm trocar site) 8 months
after surgery (score IIIb) requiring an elective open repair,
without post-operative complications (all the port access
[10 mm were closed at the end of the primary procedure
with Endo CloseTM devices). Two patients required
laparoscopic cholecystectomy 14 months and 20 months
after LSG for symptomatic gallstones (4.8%) instead of
prophylactic treatment with ursodeoxycholic acid (UDCA)
as recommend by the review and meta-analysis published
in 2008 [22]. The surgical outcomes are reported in
Table 2. The average post-operative BMI was 42.8 ± 12,
40.3 ± 9, 39.5 ± 7, 32.3 ± 10, 32.8 ± 5, 31.3 ± 8, and
29.4 ± 13 kg/m2 at 1, 3, 6, 9, 12, 18, and 24 months,
respectively. At the same post-operative time, the EWL%
were 17 ± 5, 30.1 ± 11, 42.3 ± 9, 51.5 ± 15, 58.3 ± 8,
59.6 ± 12, and 59.4 ± 6 as shown in Fig. 1. Regarding the
co-morbidities, for T2DM, hypertension and OSAS the
following results were obtained and presented as remission/
improvement/unmodified: 71/29/0% (T2DM), 75/20/5%
(Hypertension), 61/27/12% (OSAS). The mean resolution
rate of the single co-morbidity, including the previously
described, was 78.2%. The Fig. 2 represents the results of
LSG on single co-morbidity. At two-year follow-up, the
syndromic group patients (7–17.01%; mean age:
16.4 ± 2.7 years, mean pre-operative BMI = 47.3 ±
5.6 kg/m2 and excess weight = 70.6 ± 20 kg) had an
average %EWL of 15 ± 4, 26.7 ± 2, 37.8 ± 6,
48.8 ± 12, 56.6 ± 9 and 58.3 ± 8% after 1, 3, 6, 9, 12,
and 24 months, respectively, and the value at two year was
comparable with the entire population (p = 0.7) (Fig. 3).
The psychiatrist reduced the drug dosage (topiramate from a
mean dosage of 210.25 mg to a mean dosage of 85 mg at
bedtime and fluoxetine to 10 mg/day to 0 at mean post-
operative time of 16 ± 4 months) parallel the good com-
pliance to follow-up schedule and family report of eating
pattern which appeared substantially improved. The patients
with previous history of BIB placement (24–58.5%; mean
Table 1 Demographics characteristics of study group
Number of patients (N) 41
Sex (M/F) 20/21
Age (mean ± SD) 15 ± 4.8 years
Syndromic obesity (N; type) 7; 6 Prader–Willi-1 Bardet–
Biedl
Pre-operative BMI (mean ± SD) 49 ± 6 kg/m2
Pre-operative BIB placement (N/%) 24/58.5%
Patients with major co-morbidities
(N/%)
31/77%
Patients with minor co-morbidities
(N/%)
10/23%
SD standard deviations
Table 2 Operative outcomes
LSG ? HHR (N/%) 3/7.3%
Operative time 94 ±
35 min
Conversion rate (N/%) 0/0%
Intra-operative complications (N/%) 0/0%
Hospital stay (mean ± SD) 5.3 ±
2 days
Peri-/post-operative complications (N/%/Clavien–
Dindo Score)
2/4.9%/II–
IIIb
HHR hiatal hernia repair with posterior cruroplasty
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Fig. 1 Graph demonstrating
EWL% evolution in post-
operative follow-up
(mean ± SD)
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age: 18.2 ± 3.2 years, mean pre-operative BMI: 45 ±
3.7 kg/m2 and excess weight: 76 ± 17.3 kg) showed amean
%EWL of 13.5 ± 8, 28.3 ± 7, 36.5 ± 8, 43.7 ± 11,
51.3 ± 16 and 47.3 ± 9 after 1, 3, 6, 9, 12, and
24 months, respectively, and the value at two year was
considerably lower compared to the entire population
(p\ 0.01) (Fig. 4). After 2 years of follow-up, four
patients (9.7%; 2 patients with PWS) had an insufficient
weight loss (IWL = EWL\50%) had remission of co-
morbidities and are at present re-evaluated by the team
for surgical revision.
Discussion
The most effective option for adolescent morbid obese it
remains the surgical treatment. As reported in a recently
published review and meta-analysis, laparoscopic gastric
bypass (LGBP), LSG and laparoscopic adjustable gastric
banding (LAGB) remains the three surgical options [8],
considering malabsorbitive operation as potentially dan-
gerous during this growing phase of life, and therefore non-
indicated. The LGBP seems to be powerful concerning
BMI loss and co-morbidities control (T2DM resolution in
79–100% of total series) [8] but has a complications rate
(5.1% peri-operative, 17.1% re-intervention rate) higher
than the LSG and LAGB. Moreover, the iron, vitamin A, B,
D, folic acid, and zinc deficiencies together with the
presence of a blind stomach remain the major limitation of
the procedure. LAGB is a potential option for lower
complication rate but less BMI loss compared with LGBP
and LSG [9] and the presence of foreign bodies, requiring
lifelong controls, regulation and possible re-operations,
thus representing the limit of this procedure. Furthermore,
a recent comparative publication between LSG and LGBP
in late adolescents (65 patients/18–20 years; 45 subjected
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Fig. 2 Comparison of resolved,
improved and unmodified co-
morbidities. *Obstructive sleep
apnea syndrome;
**Nonalcoholic steatohepatitis;
***Previous valvular surgery;
****Polycystic ovarian
syndrome
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Fig. 3 Comparison of %EWL
at 2 year of follow-up.
Difference population* vs
syndromic patient**; p = 0.7
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to LSG and 20 to LGBP) showed a significant difference in
%EWL at 2-year follow-up; 81.0% in LGBP versus 96.8%
in LSG group without differences in complications rate
[23]. Currently, LSG is the most diffuse procedures, in
adult patients, and has higher growing rate worldwide [24].
The first review evaluating LSG in adolescents was pub-
lished in 2013, analyzing 198 patients from nine studies.
The review reports a percentage change in mean weight
loss of 31.2% at 24 months, with total co-morbidity reso-
lution rate of 70% in the absence of major complications
[25]. Raziel et al. published their experience with 32
juveniles (age 14–18 years), on whom LSG was per-
formed. The authors reported an average EWL of 81.7%
after 1 year (15 patients) with concomitant resolution of
co-morbidities in 82.4% of these and improvement in the
others and a complication rate of 6.5% (one staple line leak
and one acute cholecystitis) [26]. In the same year, Nocca
et al. published a retrospective review where LSG was
performed on 61 teenagers. An EWL of 66.7 and 78.4%
after 1 and 2 years post-operation, respectively, (52.4% of
the group) with co-morbidity resolution rate of 77.8% and
complication rate of 19% (4 cases) was observed [27]. In
the same year, Alqahtani et al. showed in 115 adolescents
(age 13–17 years) and 37 young adults (age 18–21 years) a
co-morbidity resolution or improvement, in 90.3% after
2 years without recurrence up to 3 years post surgery [28].
In 2015, Al-Sabah retrospectively evaluated 135 teenagers
(age 12–21 years) subjected to LSG. Two years post sur-
gery, a EWL of 84.7% with excellent results in co-mor-
bidities resolution (100% T2DM and 75% hypertension)
and a complication rate of 4.4% (6 cases) were noted [29].
Recently, Tsamis et al. confirmed the attractiveness of LSG
in juveniles and young adults. They obtained an EWL of
81 ± 17%, EBMIL of 96 ± 21%, and BMI difference of
-18.08 ± 4.38 kg/m2 with complete remission of co-
morbidities (100% after 3–6 months post surgery) [30]. All
these studies conclude that LSG is an attractive therapeutic
option for young patients. Our results furthers it by adding
the safety and effectiveness along with attractiveness of
LSG in adolescents and their families who affected by
severe co-morbidities (77% major, 23% minor). This study
indicates favorable results in terms of weight control (mean
% EWL of 58.3 at 1 year and 59.4 at 2 years), with
excellent outcomes in severe co-morbidity control (57.6%)
and resolution (78.2%). The attractiveness was also
emphasized by only two cases of low-grade complications
(4.9%) with scores II and III b, confirming that the man-
agement of high-risk patients in a dedicated setting reduces
dramatically the incidence of complications. Despite these
encouraging results for obese adolescent, bariatric surgery
and LSG remain absolutely controversial for syndromic
obese adolescent, particularly in patients affected by PWS.
Scheimann et al. concluded in their review that there is
little justification for subjecting PWS patients to the
potential risks of surgical interventions, thus supporting an
alternative conservative approach [31]. The major limita-
tions of the study by Scheimann et al. are principally
related to the follow-up period, to completely abandoned or
not more recommended procedures for adolescents. The
lack of effective therapeutic interventions for adolescent
with monogenic and syndromic forms of obesity exposes
children in this group to significant morbidity and mortality
secondary to severe obesity and associated conditions they
are prone to develop [32]. In our experience, bariatric
0
10
20
30
40
50
60
70
80
EWL  % population (BIB and
syndromic pts excluded) *
EWL % pts with previous BIB
***
Fig. 4 Comparison of %EWL
at 2 year of follow-up.
Difference population* vs pts
with previous BIB***; p\ 0.01
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surgery presents a hope for such children and should be
highly considered. Our data indicated significant differ-
ences in hospital stay for syndromic and non-syndromic
patients (9 ± 3 days vs 4.2 ± 1.6 days; p\ 0.05) which is
justified by different time needed to support the re-intro-
duction of oral intake and to manage a particular category
of patients with higher risk of surgical complications
related to dysautonomia, decreased ability to vomit with
risk of gastric rupture, the absence of fever during infec-
tious episodes, and altered pain threshold that may delay
the diagnosis of the complications [33]. Similar to other
larger studies [34, 35], the %EWL of syndromic obese
recorded after 2 years post surgery in our study, did not
show any difference compared with the study population
(58.3 vs. 63.4; p = 0.7). The evidence of two cases of
IWL, even without co-morbidities relapse, suggests the
possibility to adopt the two-step strategy and postpone the
second stage of BPD-DS in adult age.
The effect of LSG in PWS patients regarding excellent
weight results in the medium follow-up [34, 35] could be
explained considering the macronutrient regulation, Ghre-
lin and Peptide YY (PYY), in patients affected by this
congenital syndrome. As demonstrated by Balikcioglu
et al. these patients have fasting and postprandial hyper
ghrelinoma and an attenuated PYY response to fat, yielding
a high Ghrelin/PYY ratio [36]. Considering the hormonal
mechanism of LSG, reduction of Ghrelin level and high
postprandial PYY response [37], this consideration should
theoretically explain our excellent results, which is not
remarkably different from the non-syndromic population.
Another concern raised from our data is related to the
adolescents with previous history of BIB failure, an
endoscopic obesity treatment largely approved as reduced-
risk strategy. In our experience, the patients with previous
BIB placement have a significant lower %EWL (47.3 vs
63.4%; p\ 0.01), probably related to an adaptation of
patients to restrictive procedure and this results should be
discussed with the patients pre-operatively.
Despite reduction in excess weight loss, in high-risk
adolescents patients with super obesity, obtain an excellent
co-morbidities control seems to be the prior goal of the
procedure, per se offering the chance of future possible
revision (bridge procedure).
The major limitations of this study are related to the
retrospective analysis, limited number of syndromic ado-
lescents and the follow-up period.
Conclusions
In conclusion, LSG appears to be safe and effective treat-
ment procedure primarily for weight loss and co-morbidity
control in morbid obese teenagers. Further, results in
syndromic adolescents support the two-stage strategy. The
multidisciplinary approach is crucial to reach the optimal
outcomes. Long-term data on a larger population are nee-
ded to better define the role of LSG in this category of
patients and to confirm the effects in adults.
Compliance with ethical standards
Conflict of interest On behalf of all authors, the corresponding
author states that there is no conflict of interest.
Ethical approval All procedures performed in studies involving
human participants were in accordance with the ethical standards of
the institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
Informed consent Informed consent was obtained from all individ-
ual participants included in the study.
References
1. Reilly JJ, Kelly J (2011) Long-term impact of overweight and
obesity in childhood and adolescence on morbidity and premature
mortality in adulthood: systematic review. Int J Obes (Lond)
35(7):891–898. doi:10.1038/ijo.2010.222 (epub 2010 Oct 26)
2. Michalsky MP, Inge TH, Simmons M, Jenkins TM, Buncher R,
Helmrath M, Brandt ML, Harmon CM, Courcoulas A, Chen M,
Horlick M, Daniels SR, Urbina EM (2015) Cardiovascular risk
factors in severely obese adolescents: the teen longitudinal
assessment of bariatric surgery (Teen-LABS) Study. JAMA
Pediatr 169(5):438–444. doi:10.1001/jamapediatrics.2014.3690
3. Ogden CL, Carroll MD, Kit BK, Flegal KM (2014) Prevalence of
childhood and adult obesity in the United States, 2011–2012.
JAMA 311(8):806–814
4. Skinner AC, Skelton J (2014) Prevalence and trends in obesity
and severe obesity among children in the United States,
1999–2012. JAMA Pediatr 168:561. doi:10.1001/jamapediatrics.
2014.21
5. Toselli S, Ventrella AR, Brasili P (2012) Prevalence and tracking
of weight disorders in Italian primary school students: a three-
year follow up. Coll Antropol 36:63–67
6. Martos-Moreno GA´, Barrios V, Mun˜oz-Calvo MT, Pozo J,
Chowen JA, Argente J (2014) Principles and pitfalls in the dif-
ferential diagnosis and management of childhood obesities. Adv
Nutr 5(3):299S–305S. doi:10.3945/an.113.004853 (print 2014
May)
7. Inge TH, Zeller MH, Jenkins TM, Helmrath M, Brandt ML,
Michalsky MP, Teen-LABS Consortium et al (2014) Periopera-
tive outcomes of adolescents undergoing bariatric surgery: the
Teen-Longitudinal Assessment of Bariatric Surgery (Teen-
LABS) study. JAMA Pediatr 168(1):47–53. doi:(10.1001/jama
pediatrics.2013.4296)
8. Paulus GF, de Vaan LE, Verdam FJ, Bouvy ND, Ambergen TA,
van Heurn LW (2015) Bariatric surgery in morbidly obese ado-
lescents: a systematic review and meta-analysis. Obes Surg
25(5):860–878. doi:10.1007/s11695-015-1581-2
9. Michalsky MP, Inge TH, Teich S, Eneli I, Miller R, Brandt ML,
Teen-LABS Consortium et al (2014) Adolescent bariatric surgery
program characteristics: the Teen Longitudinal Assessment of
Bariatric Surgery (Teen-LABS) study experience. Semin Pediatr
Surg 23(1):5–10. doi:10.1053/j.sempedsurg.2013.10.020 (epub
2013 Oct 31)
Eat Weight Disord
123
10. Zeller MH, Inge TH, Modi AC, Jenkins TM, Michalsky MP,
Helmrath M et al (2015) Teen Longitudinal Assessment of
Bariatric Surgery (Teen-LABS) Consortium. Severe obesity and
comorbid condition impact on the weight-related quality of life of
the adolescent patient. J Pediatr 166(3):651–659. doi:10.1016/j.
jpeds.2014.11.022 (epub 2014 Dec 30)
11. Michalsky M, Reichard K, Inge T, Pratt J, Lenders C, American
Society for Metabolic and Bariatric Surgery (2012) ASMBS
pediatric committee best practice guidelines. Surg Obes Relat Dis
8(1):1–7. doi:10.1016/j.soard.2011.09.009
12. http://www.sicob.org/area_04_medici/60_protocolli.aspx. Acces-
sed 23 Oct 2016
13. Rosenthal RJ, Diaz AA, Arvidsson D, Baker RS, Basso N, Bel-
langer D et al (2012) International Sleeve Gastrectomy Expert
Panel Consensus Statement: best practice guidelines based on
experience of [12,000 cases. Surg Obes Relat Dis 8(1):8–19.
doi:10.1016/j.soard.2011.10.019 (epub 2011 Nov 10)
14. Falkner B, Daniels SR (2004) Summary of the fourth report on
the diagnosis, evaluation, and treatment of high blood pressure in
children and adolescents. Hypertension 44:387–388
15. Expert Panel on Integrated Guidelines for Cardiovascular Health,
and Risk Reduction in Children and Adolescents; National Heart,
Lung, and Blood Institute (2011) Expert panel on integrated
guidelines for cardiovascular health and risk reduction in children
and adolescents: summary report. Pediatrics 128(Suppl 5):S213–
S256. doi:10.1542/peds.2009-2107C (epub 2011 Nov 14)
16. American Diabetes Association (2011) Standards of medical care
in diabetes—2011. Diabet Care 34(Suppl 1):S11–S61
17. Wong TK (2011) The search on an ideal disease marker for
childhood obstructive sleep apnea syndrome. Sleep 34:133–134
18. Chervin RD, Hedger K, Dillon JE, Pituch KJ (2000) Pediatric
sleep questionnaire (PSQ):validity and reliability of scales for
sleep-disordered breathing, snoring, sleepiness, and behavioural
problems. Sleep Med 1:21–32
19. Zawadzki JK, Dunaif A (1992) Diagnostic criteria for polycystic
ovary syndrome: towards a rational approach. In: Dunaif A,
Givens JR, Haseltine FP, Merriam GR (eds) Polycystic ovary
syndrome. Blackwell, Boston, pp 377–384
20. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Work-
shop Group (2004) Revised 2003 consensus on diagnostic criteria
and long-term health risks related to polycystic ovary syndrome.
Fertil Steril 81(1):19–25
21. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D,
Schulick RD, de Santiban˜es E, Pekolj J, Slankamenac K, Bassi C,
Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M
(2009) The Clavien-Dindo classification of surgical complica-
tions: five-year experience. Ann Surg 250(2):187–196. doi:10.
1097/SLA.0b013e3181b13ca2
22. Uy MC, Talingdan-Te MC, Espinosa WZ, Daez ML, Ong JP
(2008) Ursodeoxycholic acid in the prevention of gallstone for-
mation after bariatric surgery: a meta-analysis. Obes Surg
18(12):1532–1538. doi:10.1007/s11695-008-9587-7 (epub 2008
Jun 24)
23. Van Mil SR, Biter LU, Grotenhuis BA, Zengerink JF, Mannaerts
GH (2016) Laparoscopic Sleeve Gastrectomy versus Gastric
Bypass in Late Adolescents: What Is the Optimal Surgical
Strategy for Morbid Obesity? Eur J Pediatr Surg (epub ahead of
print)
24. Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H,
Scopinaro N (2015) Bariatric surgery worldwide 2013. Obes Surg
25(10):1822–1832. doi:10.1007/s11695-015-1657-z
25. Blu¨her S, Raschpichler M, Hirsch W, Till H (2013) A case report
and review of the literature of laparoscopic sleeve gastrectomy in
morbidly obese adolescents: beyond metabolic surgery and vis-
ceral fat reduction. Metabolism 62(6):761–767. doi:10.1016/j.
metabol.2012.11.001 epub 2012 Dec 6
26. Raziel A, Sakran N, Szold A, Teshuva O, Krakovsky M, Rabau O
et al (2014) Mid-term follow-up after laparoscopic sleeve gas-
trectomy in obese adolescents. Isr Med Assoc J 16(1):37–41
27. Nocca D, Nedelcu M, Nedelcu A, Noel P, Leger P, Skalli M et al
(2014) Laparoscopic sleeve gastrectomy for late adolescent
population. Obes Surg 24(6):861–865. doi:10.1007/s11695-014-
1200-7
28. Alqahtani AR, Elahmedi MO, Al Qahtani A (2014) Comorbidity
resolution in morbidly obese children and adolescents undergoing
sleeve gastrectomy. Surg Obes Relat Dis 10(5):842–850. doi:10.
1016/j.soard.2014.01.020 (epub 2014 Jan 28)
29. Al-Sabah SK, Almazeedi SM, Dashti SA, Al-Mulla AY, Ali DA,
Jumaa TH (2015) The efficacy of laparoscopic sleeve gastrec-
tomy in treating adolescent obesity. Obes Surg 25(1):50–54.
doi:10.1007/s11695-014-1340-9
30. Tsamis D, Plastiras A, Natoudi M, Oikonomou E, Zografos G,
Leandros E, Albanopoulos K (2015) Impact of Laparoscopic
Sleeve Gastrectomy on Weight Loss and Associated Co-mor-
bidities in Adolescents and Young Adults. J Laparoendosc Adv
Surg Tech A 25(12):971–975. doi:10.1089/lap.2015.0426 (epub
2015 Nov 5)
31. Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W
(2008) Critical analysis of bariatric procedures in Prader–Willi
syndrome. J Pediatr Gastroenterol Nutr 46(1):80–83
32. Alqahtani AR, Elahmedi M, Alqahtani YA (2014) Bariatric sur-
gery in monogenic and syndromic forms of obesity. Semin
Pediatr Surg 23(1):37–42. doi:10.1053/j.sempedsurg.2013.10.013
(epub 2013 Nov 15)
33. Golstone AP, Holland AJ, Hauffa BP et al (2008) Recommen-
dations for the diagnosis and management of Prader–Willi syn-
drome. J Clin Endocrinol Metab 93(11):4183–4197
34. Alqahtani AR, Elahmedi MO, Al Qahtani AR, Lee J, Butler MG
(2015) Laparoscopic sleeve gastrectomy in children and adoles-
cents with Prader–Willi syndrome: a matched-control study. Surg
Obes Relat Dis S1550–7289(15):00301–00309. doi:10.1016/j.
soard.2015.07.014 (epub ahead of print)
35. Alqahtani A, Elahmedi M, Qahtani AR (2016) Laparoscopic
sleeve gastrectomy in children younger than 14 years: refuting
the concerns. Ann Surg 263(2):312–319. doi:10.1097/SLA.
0000000000001278
36. Gumus Balikcioglu P, Balikcioglu M, Muehlbauer MJ, Purnell
JQ, Broadhurst D, Freemark M (2015) Macronutrient regulation
of ghrelin and peptide YY in pediatric obesity and Prader–Willi
syndrome. J Clin Endocrinol Metab 100(10):3822–3831. doi:10.
1210/jc.2015-2503 (epub 2015 Aug 10)
37. Noria SF, Grantcharov T (2013) Biological effects of bariatric
surgery on obesity-related co-morbidities. Can J Surg
56(1):47–57. doi:10.1503/cjs.036111
Eat Weight Disord
123
